On Wednesday, UK-based biopharmaceutical company Amryt Pharma, which develops innovative treatments for rare diseases, made its U.S. debut on the Nasdaq, trading as AMYT. 

This isn't the company's first foray into the stock market, but CEO Joe Wiley says the expansion to the U.S. should help the company grow its business further.

"We are already listed in London, so we are now dual-listed in both the U.S. and the UK," Wiley said. "We also hope to enhance our value of our equity on both sides of the Atlantic through this dual-listing. Thirdly, we believe this enhances our credibility as a biotech company and our access to deal globally as we continue our strategy to acquire, develop, and commercialize."

One other factor contributing to Amryt Pharma's decision to go public in U.S. markets was due to where the company's shareholders are located. Roughly 70 percent of the company's shareholders are already located in North America and the company hopes to expand its reach there.

"We believe that this IPO will increase the awareness of Amryt in the U.S. by increasing our Amyrt coverage." Wiley then added, "We believe that we can access a deeper pool of capital and healthcare investors in the U.S. This will ultimately drive liquidity in our shares, which is what our goal is."   

Although not in the race to develop a COVID-19 vaccine, by focusing on rare and orphan diseases, the company believes its future is bright. As an example, Wiley pointed to his company's study of epidermolysis bullosa, a group of rare and genetic disorders of the skin, as one reason investors should remain interested.

"Analysts who cover this area believe that north of a $1 billion market opportunity...We actually did the world's largest-ever study in EB...we will read our data from that in late Q3 or early Q4 this year."

Share:
More In Business
Al Sharpton to lead pro-DEI march through Wall Street
The Rev. Al Sharpton is set to lead a protest march on Wall Street to urge corporate America to resist the Trump administration’s campaign to roll back diversity, equity and inclusion initiatives. The New York civil rights leader will join clergy, labor and community leaders Thursday in a demonstration through Manhattan’s Financial District that’s timed with the anniversary of the Civil Rights-era March on Washington in 1963. Sharpton called DEI the “civil rights fight of our generation." He and other Black leaders have called for boycotting American retailers that scaled backed policies and programs aimed at bolstering diversity and reducing discrimination in their ranks.
A US tariff exemption for small orders ends Friday. It’s a big deal.
Low-value imports are losing their duty-free status in the U.S. this week as part of President Donald Trump's agenda for making the nation less dependent on foreign goods. A widely used customs exemption for international shipments worth $800 or less is set to end starting on Friday. Trump already ended the “de minimis” rule for inexpensive items sent from China and Hong Kong, but having to pay import taxes on small parcels from everywhere else likely will be a big change for some small businesses and online shoppers. Purchases that previously entered the U.S. without needing to clear customs will be subject to the origin country’s tariff rate, which can range from 10% to 50%.
Southwest Airlines’ new policy will affect plus-size travelers. Here’s how
Southwest Airlines will soon require plus-size travelers to pay for an extra seat in advance if they can't fit within the armrests of one seat. This change is part of several updates the airline is making. The new rule starts on Jan. 27, the same day Southwest begins assigning seats. Currently, plus-size passengers can pay for an extra seat in advance and later get a refund, or request a free extra seat at the airport. Under the new policy, refunds are still possible but not guaranteed. Southwest said in a statement it is updating policies to prepare for assigned seating next year.
Load More